查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1316960

心血管药物市场：按药物类型、适应症、给药途径、购买型态和最终用户划分 - 全球预测 2023-2030

Cardiovascular Drugs Market by Drug Type, Disease Indication, Route of Administration, Mode of Purchase, End-Users - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球心血管药物市场预计将大幅成长，年复合成长率为9.13%，预计2023年将达到826.5亿美元，2030年将达到1526.1亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球心血管治疗市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.全球心血管药物市场规模及预测如何？

2.在预测期内，COVID-19对全球心血管药物市场的阻碍因素与影响为何？

3.预测期内全球心血管药物市场需要投资哪些产品/细分市场/应用/领域？

4.你们在全球心血管药物市场的竞争策略是什么？

5.全球心血管药物市场的技术趋势与法律规范是什么？

6.全球心血管药物市场主要厂商的市占率为何？

7. 哪些型态和策略性措施被认为适合进入全球心血管药物市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 心血管疾病盛行率上升
      • 加大药物研发研发投入
      • 政府努力预防和控制心血管疾病
    • 抑制因素
      • 产品召回和心血管药物的高成本
    • 机会
      • 有利的心血管药物报销政策和计划
      • 治疗心血管疾病新药介绍
    • 任务
      • 高效、安全药物开发的复杂性
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化

第6章药物市场

  • 血管紧张素抑制剂
  • 抗凝血物
  • 降血脂药物
  • 抗高血压
  • 抗血小板药

第7章药物市场：依疾病适应症

  • 心律不整
  • 冠状动脉疾病
  • 高血脂症
  • 高血压

第8章药物市场：依给药途径

  • 静脉
  • 口服
  • 皮下的

第9章药物市场依采购方式划分

  • 非处方药物
  • 处方药

第10章心血管药物市场：依最终用户分类

  • 医院药房
  • 网路药房
  • 零售药房

第11章美洲心血管药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第12章亚太心血管药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第13章欧洲、中东和非洲心血管药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争形势

  • FPNV定位矩阵
  • 市占率分析：主要企业
  • 竞争情境分析：主要企业

第15章上市公司名单

第16章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-434CCDA0519A

The Global Cardiovascular Drugs Market is forecasted to grow significantly, with a projected USD 82.65 billion in 2023 at a CAGR of 9.13% and expected to reach a staggering USD 152.61 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cardiovascular Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cardiovascular Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Type, market is studied across Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic, Antihypertensive, and Antiplatelet Drugs. The Anticoagulants commanded largest market share of 32.12% in 2022, followed by Antihypertensive.

Based on Disease Indication, market is studied across Arrhythmia, Coronary Artery Disease, Hyperlipidaemia, and Hypertension. The Coronary Artery Disease commanded largest market share of 34.23% in 2022, followed by Hyperlipidaemia.

Based on Route of Administration, market is studied across Intravenous, Oral, and Subcutaneous. The Oral commanded largest market share of 57.23% in 2022, followed by Intravenous.

Based on Mode of Purchase, market is studied across Over-The-Counter Drugs and Prescription-Based Drugs. The Prescription-Based Drugs commanded largest market share of 82.12% in 2022, followed by Over-The-Counter Drugs.

Based on End-Users, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Retail Pharmacies commanded largest market share of 67.32% in 2022, followed by Hospital Pharmacies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 37.00% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cardiovascular Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cardiovascular Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cardiovascular Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cardiovascular Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Cardiovascular Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Cardiovascular Drugs Market?

6. What is the market share of the leading vendors in the Global Cardiovascular Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Cardiovascular Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cardiovascular Drugs Market, by Drug Type, 2022 vs 2030
  • 4.3. Cardiovascular Drugs Market, by Disease Indication, 2022 vs 2030
  • 4.4. Cardiovascular Drugs Market, by Route of Administration, 2022 vs 2030
  • 4.5. Cardiovascular Drugs Market, by Mode of Purchase, 2022 vs 2030
  • 4.6. Cardiovascular Drugs Market, by End-Users, 2022 vs 2030
  • 4.7. Cardiovascular Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Prevalence of Cardiovascular Disorders
      • 5.1.1.2. Increasing R&D Investments for Drug Development
      • 5.1.1.3. Government Initiatives for Prevention & Control of Cardiovascular Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Product Recalls and High Cost of Cardiovascular Drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
      • 5.1.3.2. Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in Efficient and Safe Drug Development
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Cardiovascular Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Angiotensin Inhibitors
  • 6.3. Anticoagulants
  • 6.4. Antihyperlipidemic
  • 6.5. Antihypertensive
  • 6.6. Antiplatelet Drugs

7. Cardiovascular Drugs Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Arrhythmia
  • 7.3. Coronary Artery Disease
  • 7.4. Hyperlipidaemia
  • 7.5. Hypertension

8. Cardiovascular Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Subcutaneous

9. Cardiovascular Drugs Market, by Mode of Purchase

  • 9.1. Introduction
  • 9.2. Over-The-Counter Drugs
  • 9.3. Prescription-Based Drugs

10. Cardiovascular Drugs Market, by End-Users

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Cardiovascular Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cardiovascular Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cardiovascular Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player

15. List of Company Mentioned

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. CARDIOVASCULAR DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CARDIOVASCULAR DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
  • FIGURE 5. CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2030 (%)
  • FIGURE 6. CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
  • FIGURE 7. CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2022 VS 2030 (%)
  • FIGURE 8. CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2022 VS 2030 (%)
  • FIGURE 9. CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 10. CARDIOVASCULAR DRUGS MARKET DYNAMICS
  • FIGURE 11. CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 20. CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 21. CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CARDIOVASCULAR DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANGIOTENSIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERLIPIDEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CARDIOVASCULAR DRUGS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERLIPIDAEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 16. CARDIOVASCULAR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. CARDIOVASCULAR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CARDIOVASCULAR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 20. CARDIOVASCULAR DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. CARDIOVASCULAR DRUGS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 23. CARDIOVASCULAR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. CARDIOVASCULAR DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. CARDIOVASCULAR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 235. CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 236. CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 237. CARDIOVASCULAR DRUGS MARKET LICENSE & PRICING